Cargando…

Physiologically‐Based Pharmacokinetic Modeling Approach to Predict Rifampin‐Mediated Intestinal P‐Glycoprotein Induction

Physiologically‐based pharmacokinetic (PBPK) modeling is a powerful tool to quantitatively describe drug disposition profiles in vivo, thereby providing an alternative to predict drug–drug interactions (DDIs) that have not been tested clinically. This study aimed to predict effects of rifampin‐media...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamazaki, Shinji, Costales, Chester, Lazzaro, Sarah, Eatemadpour, Soraya, Kimoto, Emi, Varma, Manthena V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765699/ https://www.ncbi.nlm.nih.gov/pubmed/31420942 http://dx.doi.org/10.1002/psp4.12458

Ejemplares similares

Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling
por: Costales, Chester, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic modeling to evaluate in vitro‐to‐in vivo extrapolation for intestinal P‐glycoprotein inhibition
por: Yamazaki, Shinji, et al.
Publicado: (2021)

Corrigendum to: Physiologically‐based pharmacokinetic modeling to evaluate in vitro‐to‐in vivo extrapolation for intestinal P‐glycoprotein inhibition
por: Yamazaki, Shinji, et al.
Publicado: (2022)

Influence of Single Nucleotide Polymorphisms on Rifampin Pharmacokinetics in Tuberculosis Patients
por: Thomas, Levin, et al.
Publicado: (2020)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects
por: Li, Ting, et al.
Publicado: (2022)

Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein–cytochrome P450 3A4 dual substrates
por: Pan, Xian, et al.
Publicado: (2021)

Identification of Glycochenodeoxycholate 3‐O‐Glucuronide and Glycodeoxycholate 3‐O‐Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers
por: Neuvonen, Mikko, et al.
Publicado: (2020)

Verapamil and Rifampin Effect on P-Glycoprotein Expression in Hepatocellular Carcinoma
por: Jalali, Amir, et al.
Publicado: (2014)

Cytochrome P450 3A Induction Predicts P‐glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin
por: Lutz, Justin D., et al.
Publicado: (2018)

Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation
por: Xu, Rui-juan, et al.
Publicado: (2021)

Robust physiologically based pharmacokinetic model of rifampicin for predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney
por: Asaumi, Ryuta, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
por: Gerner, Bettina, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
por: Yamazaki, Shinji, et al.
Publicado: (2022)

Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects
por: Mukai, Mayumi, et al.
Publicado: (2017)

Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis
por: Sloan, Derek J., et al.
Publicado: (2017)

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
por: Ford, S. L., et al.
Publicado: (2017)

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
por: Srivastava, Shashikant, et al.
Publicado: (2022)

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers
por: Pithavala, Y. K., et al.
Publicado: (2009)

Effects of rifampin coadministration on the pharmacokinetics of digoxin: a real-world data approach
por: Oh, JungJin, et al.
Publicado: (2023)

Etymologia: Rifampin
por: Henry, Ronnie
Publicado: (2018)

Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
por: Townsend, Robert, et al.
Publicado: (2016)

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
por: Bruderer, Shirin, et al.
Publicado: (2011)

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates
por: Tan, Ming‐Liang, et al.
Publicado: (2018)

Rifampin-resistant Meningococcal Disease
por: Rainbow, Jean, et al.
Publicado: (2005)

Rifampin-resistant Neisseria meningitidis
por: Taha, Muhamed-Kheir, et al.
Publicado: (2006)

An Overlooked Cause of Rifampin Resistance
por: Agha, Yasmine Hussein, et al.
Publicado: (2020)

Rifampin-Associated Renal Failure
por: Miller, Kathleen, et al.
Publicado: (2023)

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis
por: Schaaf, Hendrik Simon, et al.
Publicado: (2009)

Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study
por: Heysell, Scott K, et al.
Publicado: (2022)

Highly Synergistic Effects of Melittin With Vancomycin and Rifampin Against Vancomycin and Rifampin Resistant Staphylococcus epidermidis
por: Mirzaei, Rasoul, et al.
Publicado: (2022)

Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B
por: Nakayama, Shinji, et al.
Publicado: (2023)

Potential Pharmacokinetic Effect of Chicken Xenobiotic Receptor Activator on Sulfadiazine: Involvement of P-glycoprotein Induction
por: Li, Mei, et al.
Publicado: (2022)

Influence of Rifampin‐Mediated Organic Anion‐Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan
por: Juif, Pierre‐Eric, et al.
Publicado: (2019)

Characterization of rifampin-resistant Staphylococcus aureus nasal carriage in patients receiving rifampin-containing regimens for tuberculosis
por: Huang, Yu-Tsung, et al.
Publicado: (2018)

Pharmacodynamic Biomarkers for Quantifying the Mycobacterial Effect of High Doses of Rifampin in Patients with Rifampin-susceptible Pulmonary Tuberculosis
por: Said, Bibie N, et al.
Publicado: (2021)

Delayed Rifampin Administration in the Antibiotic Treatment of Periprosthetic Joint Infections Significantly Reduces the Emergence of Rifampin Resistance
por: Darwich, Ali, et al.
Publicado: (2021)

Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
por: Zhou, Xiaofei, et al.
Publicado: (2017)

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants
por: Li, Jia, et al.
Publicado: (2020)

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cp0gettfae1d8o78asjo6emkct